Print This Post
In a study funded by the National Institute for Health Research (NIHR) and the Australian NHMRC, almost £2.5m has been awarded to fund a trial to assess the clinical and cost-effectiveness of memantine in patients with dementia with Lewy bodies (DLB) and patients with Parkinson’s disease dementia (PDD).
The study will be led by Professor John-Paul Taylor, Deputy Lead for the NIHR Newcastle Biomedical Research Centre’s (BRC) Dementia theme. John-Paul is also Professor of Translational Dementia Research at Newcastle University and Honorary Consultant in Old Age Psychiatry with the Cumbria, Northumberland, Tyne and Wear (NTW) NHS Trust.
The trial, COmBinging memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT), will be carried out across 25 NHS sites in England and Scotland, and five sites in Australia. The aim is the examine the effectiveness of memantine as a treatment for those living with DLB and PDD, and will begin recruiting in Autumn 2021.
NIHR
UK DRI